ALAMEDA, Calif., Feb 18, 2003 (BUSINESS WIRE) -- Calypte Biomedical Corporation (OTCBB:CALY), ...., announced the results of the special shareholder meeting held on Friday, February 14, 2003 at the company's headquarters. The shareholder measure to increase the authorized number of Calypte's common shares was passed by a majority vote.
Separately, Calypte announced preliminary unaudited results. Revenues for the quarter ended December 31, 2002 are anticipated to be approximately $800,000. This represents sequential revenue growth of approximately 60% for the fourth quarter 2002 compared to the third quarter 2002. Revenues for the year ended December 31, 2002 are anticipated to be approximately $3.6 million. The net loss attributed to common stockholders for the quarter ended December 31, 2002 is anticipated to be approximately $6.3 million. The net loss attributed to common stockholders for the year ended December 31, 2002 is anticipated to be approximately $13.4 million.
The shareholder approval to authorize additional shares for funding our future shows the faith our investors have in Calypte's objectives
Further details outlining the company's fourth quarter and year-end 2002 results will be discussed on February 27, 2003, during its scheduled earnings announcement at 8:00 am (PDT), 11:00 am (EDT).
sorry, vielleicht hat ja jemand schon das Original gepostet,aber die billige Systranübersetzung ist nur verwirrend.Klar ist ,dass mit Hilfe der Hauptversammlung die Aufstockung von derzeit-waren es 200 Millionen?- auf 800 Millionen Shares genehmigt wurde und der Verlust im letzten Jahr trotz der ständigen Verwässerung durch Convertible Bonds noch immer bei 13 Millionen lag. |
Thread abonnieren
